Abrupt switching from venlafaxine to duloxetine in the treatment of major depressive disorder

被引：0
作者：
Perahia, DGS
Kajdasz, DK
Barradell, C
Gandhi, P
Wohlreich, M
Fava, M
机构：
[1] Lilly Res Ctr Ltd, Surrey, England
[2] Gordon Hosp, London, England
[3] Lilly Res Labs, Indianapolis, IN USA
[4] Eli Lilly & Co, Basingstoke, Hants, England
[5] Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, Boston, MA 02114 USA
来源：
JOURNAL OF PSYCHOPHARMACOLOGY | 2005年 / 19卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A46 / A46
页数：1
相关论文
共 50 条
  • [21] Duloxetine in the long-term treatment of major depressive disorder
    Raskin, J
    Goldstein, DJ
    Mallinckrodt, CH
    Ferguson, MB
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (10) : 1237 - 1244
  • [22] PREDICTORS OF DULOXETINE TREATMENT PERSISTENCE FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER
    Gelwicks, S. C.
    Faries, D. E.
    Ye, W.
    Liu, X.
    VALUE IN HEALTH, 2009, 12 (03) : A181 - A181
  • [23] Duloxetine in the treatment of major depressive disorder: Comparisons of safety and efficacy
    Bailey, RK
    Mallinckrodt, CH
    Wohlreich, MM
    Watkin, JG
    Plewes, JM
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2006, 98 (03) : 437 - 447
  • [24] Venlafaxine XR versus escitalopram treatment of major depressive disorder
    Zarra, J
    Schmidt, L
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S394 - S395
  • [25] Escitalopram versus venlafaxine XR in the treatment of major depressive disorder
    Montgomery, S.
    Andersen, H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S233 - S233
  • [26] Escitalopram vs venlafaxine XR treatment of major depressive disorder
    Montgomery, SA
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S207 - S207
  • [27] An open-label study of duloxetine for the treatment of major depressive disorder - Comparison of switching versus initiating treatment approaches
    Wohlreich, MM
    Martinez, JM
    Mallinckrodt, CH
    Prakash, A
    Watkin, JG
    Fava, M
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (06) : 552 - 560
  • [28] Duloxetine: clinical efficacy, safety and tolerability in treatment of major depressive disorder
    Tarolla, E.
    Brugnoli, R.
    Pancheri, P.
    JOURNAL OF PSYCHOPATHOLOGY-GIORNALE DI PSICOPATOLOGIA, 2007, 13 (02): : 258 - 278
  • [29] The combination of duloxetine and bupropion for treatment-resistant major depressive disorder
    Papakostas, GI
    Worthington, JJ
    Iosifescu, DV
    Kinrys, G
    Burns, AM
    Fisher, LB
    Homberger, CH
    Mischoulon, D
    Fava, M
    DEPRESSION AND ANXIETY, 2006, 23 (03) : 178 - 181
  • [30] Remission rates during treatment with duloxetine in patients with major depressive disorder
    Lu, Y
    Tran, P
    Detke, M
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S214 - S214
12345